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p53 gene expresses several protein isoforms modulating p53-mediated responses through regula-
tion of gene expression. Here, we identify a novel p53 isoform, D160p53, lacking the ﬁrst 159 resi-
dues. By knockdown experiments and site-directed mutagenesis, we show that D160p53 is encoded
by D133p53 transcript using ATG160 as translational initiation site. This hypothesis is supported by
endogenous expression of D160p53 in U2OS, T47D and K562 cells, the latter ones carrying a prema-
ture stop codon that impairs p53 andD133p53 protein expression but not the one ofD160p53. Over-
all, these results show that the D133p53 transcript generates two different p53 isoforms, D133p53
and D160p53.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumour suppressor p53 protein maintains genomic and cel-
lular integrity [1]. Besides the classical p53 protein, the human p53
gene expresses several isoforms [2]. Three N-termini (TA, D40,
D133) can be combined to three distinct C-termini (a, b, c), the
six variations resulting from usage of alternative promoters, splic-
ing sites or translational initiation sites [3]. TA forms contain trans-
activation domain (TAD), which is partially or entirely lacking in
D40 and D133 forms respectively, and a forms include an oligo-
merisation domain, replaced by new residues in b and c forms
[2,4]. The expression of several p53 isoforms, together with their
production mechanism and their structural organisation, is con-
served through evolution [5]. In humans, p53 isoforms are ex-
pressed in a tissue-dependent manner and their expression is
deregulated in cancers [2,6]. Altogether, these observations indi-
cate that p53 isoforms have important functions.
The D133p53a isoform is generated by an internal promoter lo-
cated within p53 gene [2]. Through direct binding, p53 regulates
internal promoter activity thus inducing D133p53 expression in
response to stress, both in zebraﬁsh and in human cells [7–9]. Fur-
thermore, several studies suggested a role of D133p53 in p53-
mediated response. In human ﬁbroblasts, knockdown ofchemical Societies. Published by E
, DNA-binding domain; OD,
rdon).D133p53 expression promoted replicative senescence through
modulation of mir-34 expression, a p53-target gene [10]. In re-
sponse to stress, induction of D133p53a resulted in a p53-medi-
ated G2 cell-cycle arrest with inhibition of p53-mediated
apoptosis and G1 arrest, by modulating expression of some p53-re-
lated genes [7,8]. These observations suggest that D133p53a is
part of an auto-regulatory feedback loop, where p53 induces
D133p53a expression to regulate its own transcriptional activity
thus triggering adequate responses to stress. In previous report,
we observed that ectopic expression of D133p53a resulted in
detection of a band doublet, which decreased in cells treated with
a D133p53-speciﬁc siRNA [8]. Here, we identify the upper band as
D133p53a and the lower band as a novel p53 isoform, D160p53a.2. Materials and methods
2.1. Cell lines and plasmids
The human U2OS (wild-type p53), T47D (mutant p53L194F)
and H1299 (p53-null) cells were maintained at 37 C in DMEM
medium supplemented by 10% foetal calf serum (FCS) and 0.5%
gentamycin under 5% CO2 atmosphere. Doxorubicin treatment
was performed as previously described [8]. The U2OS-D133p53a
cells stably express D133p53a isoform and selective pressure is
maintained by addition of 0.5 mg/ml neomycin in culture medium
[8]. The human erythroleukaemic K562 cells were maintained
at 37 C in RPMI medium supplemented by 10% FCS, 2 mMlsevier B.V. All rights reserved.
Fig. 1. Effect of D133p53 knockdown on the detection of a band doublet. (A) Knockdown of D133p53 expression in wild-type p53 U2OS-D133p53a cells, stably expressing
D133p53a isoform. U2OS-D133p53a cells were transfected with either a non-relevant siRNA (siNS) or a siRNA targeting D133p53 transcripts (siD133). Expression of D133
forms was analysed at mRNA levels by real time PCR (left panel) (Supplementary Table I) and at protein levels by western blot using SAPU antibody recognising all p53
isoforms (right panel) (see [5] for description of p53 isoforms antibodies). Compared to siNS, siD133 treatment decreased the protein band doublet detected at 35 and 32 kDa.
Ku80: loading control; *: P-value <0.05. (B) Knockdown of endogenous D133p53 expression in the parental U2OS cells in response to doxorubicin treatment. The parental
U2OS cells were transfected with siRNAs as described in (A) and exposed to doxorubicin treatment to induce endogenous D133p53 protein, as previously described [8,9].
Analysis of protein expression using CM1 antibody speciﬁc of all p53 isoforms revealed a decrease of the band doublet in cells transfected with siD133 compared to the ones
transfected with siNS. CM1*: long exposure compared to CM1. (C) Knockdown of endogenous D133p53 expression in T47D cells, as described in (A). The endogenous band
doublet was detectable using DO-12 antibody speciﬁc of all p53 isoforms without any drug treatment. Compared to siNS, the band doublet signal decreased in siD133 treated
cells but not in response to siTA, speciﬁcally targeting TAp53 mRNA forms (see Fig. 5 for localisation of p53 siRNAs). DO-12*: long exposure.
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under 5% CO2 atmosphere. The differentiation of K562 cells was
induced by addition of 50 lM Hemin for 96 h into 3.105 cells.
D133p53a transcripts issued from a mix of ﬁve normal human
tissues were previously cloned in a pSV expressing vector (pSV-
D133p53a) [2]. D133p53a and D133p53b mRNAs expressed in
K562 cells were introduced into the same vector (pSV-K562a and
pSV-K562b, respectively). In these plasmids, point mutations were
introduced by site-directed mutagenesis to insert a premature stop
codon at residue 255 (I255X) or replace methionine residue by a
leucine at codon 133 (M133L) or codon 160 (M160L). pEGFP-N1
was used as a control of transfection efﬁciency.
Oligofectamine (Invitrogen) and Fugene (Roche) were used to
introduce into cells 50 nM of siRNAs (Supplementary Table I) or
1 lg of expressing vectors, respectively.
2.2. Real-time PCR
Total RNAs were extracted using the RNeasy Mini Kit (Qiagen).
Reverse transcription was performed on 1 lg of total RNAs using
the SuperScriptII (Invitrogen) at 42 C. Quantiﬁcation of D133p53
mRNA levels was carried out by real-time PCR on MX3000P appa-
ratus (Stratagene). Brieﬂy, 10 ng of cDNAs were ampliﬁed using
0.8 lM primers, 0.4 lM probes (Supplementary Table I) and 1X
TaqMan Universal Master Mix (Applied Biosystem). The DDCt
method was used to determine the fold change of D133p53 mRNA
levels using TBP as the reference gene. The D133p53 mRNA levelswere measured in triplicate on three independent experiments and
compiled to perform statistical analysis (t-student test). A signiﬁ-
cant difference was reach for a P-value <0.05. Detection of p53 iso-
forms was assessed by nested PCR on 100 ng of cDNAs using
160 nM primers (Supplementary Table I) and 1X PCR SuperMix
(Invitrogen).
2.3. Western blot and immunoﬂuorescence
Proteins were extracted by scrapping and syringing cells in 1X
NuPAGE LDS buffer (Invitrogen). Thirty micrograms of protein ex-
tracts were separated on pre-cast 10% NuPAGE gels (Invitrogen).
Monoclonal mouse DO-1 antibody was used to detect the classical
p53 isoform, since it epitope in TAD is lacking in D40p53 and
D133p53 [5]. Polyclonal sheep SAPU and monoclonal mouse DO-
12 antibodies detect all p53 isoforms, while monoclonal BP53.10
and KJC8 antibodies recognise a and b forms, respectively. Mono-
clonal mouse MAI antibody was speciﬁcally designed to hybridize
ATG160. Globin and c-myc (Santa-Cruz) were used as controls
of differentiation. Monoclonal mouse Ku80 and GFP (AbCam)
were used as controls of loading and of transfection efﬁciency,
respectively.
H1299 cells seeded on two-well glass chamber slides (Lab Tek)
were transfected and 48 h latter, ﬁxed by 1% formaldehyde. After
permeabilization with 0.1% Triton X-100 in 1X PBS, cells were incu-
bated 1 h with the monoclonal DO-12 antibody and then for 1 h
with FITC-conjugated anti-IgG (Jackson Immuno-chemicals).
Fig. 2. D133p53 transcript encodes a second p53 isoform, D160p53. (A) Role of D133p53 transcript in expression of the band doublet in U2OS cells. Point mutations were
introduced by site-directed mutagenesis in pSV-D133p53a expressing vector. Substitution of the methionine (ATG) at codon 133 by a leucin (CTG, M133L) abolished the
expression of D133p53a protein (35 kDa-band), while introduction of a premature stop at codon 255 (I255X) abolished the expression of the band doublet. (B) Role of codon
160 in expression of the 32 kDa-protein in p53-null H1299 cells. Substitution of the methionine by a leucine at codon 160 (M160L) abolished the expression of the 32 kDa-
protein but not the one of the 35 kDa-band corresponding to D133p53a isoform. GFP: control of transfection efﬁciency. (C) Schematic representation of the D133p53a
transcript. The D133p53a transcript holds a downstream methionine residue at codon 160 (red) that is included in a Kozak environment conserved through evolution (bold
letter).
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To determine the relation between detection of the band dou-
blet and expression of D133p53a transcript, we performed siRNA
experiment in wild-type p53 U2OS-D133p53a cells, which stably
express D133p53a at a detectable level [8]. We observed that
siD133 treatment targeting D133p53 transcripts resulted in a sig-
niﬁcant 50% decrease of D133p53 mRNA levels, compared to treat-
ment with a non-relevant siRNA (siNS) (Fig. 1A, left panel). This
diminution at mRNA levels was associated with a decreased inten-
sity of a band doublet observed by western blot (35 and 32 kDa),
suggesting that D133p53a mRNA encodes two protein products
(Fig. 1A, right panel). The same decrease of the band doublet was
observed in the parental U2OS expressing endogenous D133p53a
in response to siD133 treatment, coupled to doxorubicin treatment
(used to detect endogenous D133p53 levels [8]) (Fig. 1B). In T47D
cells, where the endogenous band doublet is detectable without
any drug treatment (Fig. 1C), its signal decreased in presence of
siD133 but not in presence of a TAp53-speciﬁc siRNA (siTA, local-
isation Fig. 5). Altogether, these observations indicate that in sev-
eral cells, the band doublet corresponds to p53 protein products
generated by D133p53 transcript.To determine whether D133p53a isoform corresponds to the
35 kDa-band and/or to the 32 kDa-band, we introduced point
mutations in pSV-D133p53a expressing vector. Methionine at co-
don 133 was replaced by a leucine (M133L) to abolish D133p53a
protein expression. In U2OS, introduction of wild-type pSV-
D133p53a vector resulted in detection of the band doublet
(Fig. 2A), support the notion, like for knock-down expression of
D133p53 mRNA, that D133p53 transcript encodes two p53 iso-
forms. In addition, we observed that the 32 kDa-band was of weak-
er intensity than the 35 kDa one. Mutation M133L resulted in loss
of the 35 kDa-band, thus corresponding to D133p53a. However,
the 32 kDa-band was still detectable and showed an increased
intensity compared to wild-type pSV-D133p53a transfection. To
determine whether the 32 kDa-band was produced by D133p53
transcript, a premature stop codon was introduced at residue
255 (I255X) that led to loss of the band doublet (Fig. 2A). Taken to-
gether, siRNA and site-directed mutagenesis experiments suggest
that the 35 kDa-band corresponds to D133p53a protein isoform.
In addition, it indicates that the 32 kDa-band is a p53 protein prod-
uct generated by D133p53a transcript that does not correspond to
D133p53a protein. Thus, D133p53 transcript produces two dis-
tinct p53 protein isoforms. These observations evoke those of
Fig. 3. p53 mutation status in K562 cell line. (A) Expression of p53 isoforms mRNAs by nested RT-PCR. K562 cells express p53a, D133p53a and D133p53b transcripts. Actin:
control of reverse transcription efﬁciency. (B and C) p53 mutation status. Mutation in D133p53 transcripts expressed in K562 cells was determined by sequencing. An
insertion at codon 136 (B, blue in C) introduces a frameshift leading to a premature stop at codon 148 (C, bold sequence: new residues due to the frameshift mutation) [13].
D133p53 transcripts expressed in K562 cells retains the open reading frame starting at codon 160 (bold red) and an intact Kozak environment (red line).
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D40p53 isoform using ATG40 from p53 transcript [4]. In the open
reading frame of the human D133p53a mRNA, a second methio-
nine is present at codon 160, which is contained within a Kozak’s
consensus motif conserved through evolution (75% similarities)
(Fig. 2B) [11]. To investigate the role of ATG160 in production of
a novel p53 isoform, we raised an antibody speciﬁc of the
ATG160 (MAI). We observed that MAI antibody detected the
32 kDa-band in presence of mutant M133L, which expressed the
highest level of the 32 kDa-band (Fig. 2A). However, the 32 kDa-
band was not detected with the MAI antibody in presence of the
premature stop codon (I255X), indicating that ATG160 is accessible
for antibody recognition. In addition, methionine 160 was substi-
tuted by a leucine into pSV-D133p53a vector. To avoid endoge-
nous p53 isoform expression, we transfected H1299 cells with
both wild-type or mutant pSV-D133p53a and GFP, which was
detectable in all conditions indicating an effective transfection
(Fig. 2C). As previously shown, pSV-D133p53a produced the band
doublet and pSV-D133p53aM133L did not generate the 35 kDa-
band, thus corresponding to D133p53a protein isoform. Moreover,
while mutation M160L had no effect on D133p53a expression, it
resulted in loss of the 32 kDa-band. This suggests that the
32 kDa-band corresponds to a p53 isoform initiated at ATG160
and we named it, D160p53a. We next attempted to identify cell
line expressing exclusively D160p53 isoform. Using the IARC
TP53 Database, a list of mutant p53 cells was established that pres-
ent premature stop between codons 133 and 160, either by non-
sense mutation or insertion/deletion [12]. It drew our attention
to the erythroleukaemic K562 described as p53-null because of
the presence of a premature stop codon [13]. Using nested PCR,
we ﬁrst showed that K562 cells express three p53 transcripts,
p53a, D133p53a and D133p53b (Fig. 3A). Sequencing of both
D133p53a and D133p53b transcripts conﬁrmed the insertion of
a cytosine into codon 136 that results in a premature stop codonat residue 148 (Fig. 3B and C) [13]. As expected, this frameshift
mutation avoids expression of both p53 and D133p53 proteins
(Fig. 4A and B). Nevertheless, mutant D133p53 transcripts ex-
pressed in K562 cells retains the wild-type open reading frame ini-
tiated at ATG160 (Fig. 3C, red line). To determine whether K562
D133p53 transcripts can produce D160p53 protein, they were
cloned into pSV expression vector (pSV-K562a or -K562b) and
point mutation M160L was introduced to abolish usage of
ATG160 as initiation site of translation (pSV-K562aM160L).
H1299 cells transfected with pSV-K562a or pSV-K562b plasmids
expressed a p53 protein product (Fig. 4B). However, p53 protein
product expression was lost in cells transfected with pSV-
K562aM160L, while control of transfection efﬁciency was still
detectable (Fig. 4C). These observations indicate that mutant
D133p53 transcripts expressed in K562 cells conserves the ability
to generate p53 isoforms initiated at codon 160, D160p53a and
D160p53b.
Using immunoﬂuorescence, we compared the subcellular local-
isation of D160p53 isoforms to that of D133p53. To avoid any
interplay with endogenous p53, analysis was performed in p53-
null H1299 cells transfected either with pSV-D133p53a/b or with
pSV-K562a/b plasmids (Fig. 4D). As already described, D133p53a
and D133p53b signals were concentrated in the nucleus, the latter
one presenting a foci pattern in about 10% of cells [2]. Transfection
of pSV-K562a or pSV-K562b plasmids produced a strong nuclear
signal, as observed for D133p53a and D133p53b isoforms. In addi-
tion, D160p53a presented a perinucleolar pattern, while
D160p53b formed foci in some cells. Based on the distinct localisa-
tion of D133p53b and D160p53b, it indicates that foci formation is
dependent on the b peptide in short N-terminal p53 isoforms [2].
Finally, we investigated the expression of endogenous D160p53
isoforms in K562 cells in response to hemin treatment. Hemin
promotes erythrocyte differentiation, as shown by concomitant de-
crease of c-myc and increase of haemoglobin expression (Fig. 4E)
Fig. 4. Properties of D160p53 isoforms expressed in K562 cells. (A) Lack of the canonical p53 protein. Analysis of p53 expression proﬁle using DO-1 antibody speciﬁc of the
canonical p53 protein conﬁrmed the lack of p53 expression in K562, like in p53-null leukaemia U937 and P39 cells. U2OS: positive p53 control. (B) Expression of p53 protein
products by mutant D133p53 mRNAs expressed in K562 cells. D133p53a and D133p53bmRNA expressed in K562 cells were cloned into an expressing vector (pSV-K562a or
pSV-K562b) and transfected in p53-null H1299 cells. pSV-K562a and pSV-K562b plasmids express p53 protein products at 32 and 26 kDa, respectively. (C) Determination of
internal initiation of translation at ATG160 in K562 D133p53a transcript. Substitution of the methionine at codon 160 by a leucine (M160L) was introduced in pSV-K562a to
abolish usage of ATG160 as internal initiation site of translation. In p53-null H1299 cells, the 32kD-band was detected in cells transfected with wild-type pSV-K562a but not
with the M160L one, conﬁrming that the 32 kDa-band corresponds to D160p53a. (D) Subcellular localisation of D160p53 isoforms. pSV-K562a and pSV-K562b expressing
vectors were transfected in H1299 cells and localisation of D160p53 proteins analysed by immunoﬂuorescence using DO-12 antibody. Both D160p53a and D160p53b were
localised in the nucleus, like D133p53a and D133p53b. However, D160p53a presented a perinucleolar localisation and D160p53b exhibited foci pattern in some cells, as
already reported for D133p53b [2]. White scale: 10 lM. (E) Expression of endogenous D160p53 isoforms. Differentiation of K562 cells was induced by hemin treatment as
shown by c-myc and globin expression, as already described [14]. D160p53a isoform was detected using the a form-speciﬁc BP53.10 antibody and D160p53b isoform using
the b form-speciﬁc KJC8 antibody. In response to hemin-induced differentiation in K562 cells, D160p53b isoform expression level was reduced compared to in K562 non-
treated cells.
V. Marcel et al. / FEBS Letters 584 (2010) 4463–4468 4467[14]. In K562 cells, both endogenous D160p53a and D160p53b
were detected using a or b-forms speciﬁc antibodies. Moreover,
D160p53b expression was decreased in response to hemin treat-
ment, suggesting regulation of D160p53b expression during
hemin-mediated differentiation (Fig. 4E).
Here, we report that D133p53 transcript can express two p53
protein isoforms, D133p53 and D160p53 (Fig. 5). By site-directed
mutagenesis, we demonstrated that the human ATG160, present
in a Kozak environment conserved through evolution, is used to
produce the novel D160p53 isoform. D160p53a can be detected
in several cell lines, including K562, despite the presence of a pre-
mature stop at codon 148. In addition, K562 cells express C-termi-nal variant D160p53b, which is repressed by hemin treatment.
Further experiments will be required to investigate the regulation
of D160p53b expression during hemin-mediated differentiation. In
addition, it is important to note that the previous studies showing
the biological implication in the regulation of p53-mediated senes-
cence, apotosis and G1 cell cycle arrest, have been performed using
knock-down approaches based on the usage of two siRNAs speciﬁc
of the D133p53 mRNA. Thus, it will remain important to decipher
whether the biological effects observed are associated to D133p53
and/or D160p53. In theory, a third D160p53 isoform remains to be
identiﬁed exhibiting a C-terminal c peptide (D160p53c), since
D133p53 transcript has been shown to present three different
Fig. 5. The human p53 isoforms. The human p53 gene contains a proximal (P1) and an internal (P2) promoter, regulating the expression of p53 and D133p53 transcripts,
respectively. The p53 transcript encodes two p53 isoforms: p53 and A40p53, produced by internal initiation of translation using ATG 40 encompassing in a Kozak
environment [4]. The D133p53 transcript encodes both D133p53 and D160p53 isoforms. D160p53 protein isoform lacks the entire transactivation domain and part of the
DNA-binding domain, which encompasses the conserved domain II. D160p53 can be expressed with at least two different C-terminal domains, a and b. D160p53c isoform
remains to be identiﬁed. siTA and siD133, sequences targeted by the siRNAs used in the study; TAD, transactivation domain (I and II); PXXP, proline-rich domain; DBD, DNA-
binding domain; NLS, nuclear localisation signal; OD, oligomerisation domain; grey boxes, p53 conserved domains through evolution (from I to V).
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-end encoding a, b or c peptides [2]. Taken together, this
study shows that p53 gene can express at least 11 isoforms, with
the identiﬁcation of two additional isoforms, D160p53a and
D160p53b.
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